Abpro Holdings shares surge 18.29% after-hours after FDA clears Phase 1 trial for ABP-102/CT-P72.

Abpro Holdings surged 18.29% in after-hours trading following the announcement of FDA clearance for its lead oncology program ABP-102/CT-P72. The regulatory milestone permits initiation of Phase 1 trials to evaluate the therapy’s safety and efficacy in HER2-positive tumors, a significant step in drug development. The program, co-developed with Celltrion Inc., targets a global market and demonstrated preclinical potential in resistant tumor models. The clearance validates the company’s pipeline progress and strengthens its position in oncology innovation, likely driving investor optimism.